Ezia Bello - Concepedia

Author

Ezia Bello

Mario Negri Institute for Pharmacological Research ORCID

Also Known As

Bello, E., Bello, Ezia, E Bello, E. Bello, Elena Bello, Ezia Bello

101

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Mario Negri Institute for Pharmacological Research Istituti di Ricovero e Cura a Carattere Scientifico University of Milan Fondazione IRCCS Istituto Nazionale dei Tumori PharmaMar (Spain)

About

Ezia Bello is an author at Mario Negri Institute for Pharmacological Research specializing in medicine, pharmacology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	625
2	Engineering	4	4	88
3	Biomedical Engineering	3	3	72
4	Biochemistry	1	1	92
5	Biomolecular Engineering	1	1	23

Ezia Bello

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models Cristina Belgiovine, Ezia Bello, Manuela Liguori, British Journal of Cancer	2017	149
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action Elena Campaner, Alessandra Rustighi, Alessandro Zannini, Nature Communications	2017	142
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models Ezia Bello, Gennaro Colella, Valentina Scarlato, Cancer Research Antitumor ActivityFamily MembersPotent Dual InhibitorCancer BiologyTumor Biology	2011	141
Mode of action of trabectedin in myxoid liposarcomas Silvia Di Giandomenico, Roberta Frapolli, Ezia Bello, Oncogene Surgical PathologyHistopathologyPathologyTrabecular MeshworkMedicine	2013	128
Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials Ghassan M. Sulaiman, Khulood W. Al Sammarrae, Ali H. Ad’hiah, Food and Chemical Toxicology Food ChemistryAntioxidant PotentialsBiochemistryMedicineChemical Composition	2011	92
Comparison of <i>in vitro</i> and <i>in vivo</i> biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104) Michela Romano, Roberta Frapolli, Monique Zangarini, International Journal of Cancer	2013	61
The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts Ezia Bello, Giulia Taraboletti, Gennaro Colella, Molecular Cancer Therapeutics	2012	44
A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells Isabella Orienti, Valentina Salvati, Giovanni Sette, Journal of Experimental & Clinical Cancer Research	2019	40
Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo Ghassan M. Sulaiman, Ali H. Ad’hiah, Khulood W. Al-Sammarrae, Food and Chemical Toxicology MedicinePathologyPharmacologyAnti-tumour PropertiesIraqi Propolis	2012	38
Promising <i>in vivo</i> efficacy of the BET bromodomain inhibitor OTX015/MK‐8628 in malignant pleural mesothelioma xenografts Ramiro Vázquez, Simonetta Andrea Licandro, Lucile Astorgues‐Xerri, International Journal of Cancer Chemoprevention StrategyGliomaC-myc InhibitorsMedicineC-myc Protein Levels	2016	38

Page 1